Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Like a diagnostic test, regeneron will not be the only drug used. It's an intravenous delivery unlike Foralumab which can be administered as oral or inhaler....much cheaper and probably more effective. Space for many suppliers including TILS!
People are Obsessed with covid.... TILS was never even about covid.... So it's really irrelevant.
Foralumab is much more that covid.
Dont know if thats good or bad for tils to be fair?
In the article Astro provided it states that the price of 11$ is only for the following.
Foralumab just treating chrohns disease
Miliclib and just treating hcc
Tzls-501 not accounted for .
accustem sciences not accounted for.
What does this mean.....
The 11 dollars in reality is a valuation for just foralumab treating one disease.... And Miliclib just treating one type of cancer.
Yet as we know foralumab can assist with
NASH
MS
LUPUS
RA
PSORIASIS
GVHD
IBD
No Value has been attributed to treating these conditions.
Or treating covid......
The 11 dollars covers around 20 percent of TILS potential...... Its mind boggling.
Wow.. ... This really is a Giant..... All this for 160p
Mental.
Very soon when we get results... A real pharma company will appreciate the value here and no one will get chance to get a share less that £10 IMO.
Do your own research.
Im brimming with antisipation for a possitive rns to make this company truly fly ive been holding since june or july last year and have added a few times.im hoping they fly i want to put a deposit on a house lol come on tils you can do it!
So when you doubt yourself.... And you see the manipulation in the market.... And the price drops..... Just know its temporary... And its planned.... Don't fall victim.... These are premium Shares and the guys with deep pockets can control this... But they can't if you keep hold of them.... Only control they have will have then is to put the priceup. Genuinely.
Tiziana Life Sciences PLC (TLSA) Rating: Buy
Raghuram Selvaraju, January 19, 2021
H.C.WAINWRIGHT&CO gives TLSA a buy rating and price target of $11
https://ir.tizianalifesciences.com/static-files/e6006275-cfa2-455a-8cc7-3221a7ea6883
Covid-19: Germany to begin experimental antibodies treatment used in treating former US President Donald Trump
Germany will become the first European Union country to start using the same experimental antibodies treatment credited with helping Donald Trump recover from Covid-19, health minister Jens Spahn said Sunday.
"The government has bought 200,000 doses for 400 million euros ($486 million)," Spahn told the Bild am Sonntag newspaper, working out at 2,000 euros per dose.
The so-called monoclonal antibody ****tails will be deployed to university hospitals in the coming week, he said, adding that Germany was "the first country in the EU" to use them in the fight against the pandemic.
Spahn did not name the manufacturer that will be supplying the drugs but confirmed it was the same medicine given to then-US president Trump when he fell ill with Covid last October.
"They work like a passive vaccination. Administering these antibodies in the early stages can help high-risk patients avoid a more serious progression," Spahn said.
Trump, who was briefly hospitalised with the coronavirus, was given the antibody therapy developed by US firm Regeneron, known as REGN-COV2, even before the treatment had won regulatory approval.
He later said the medicine did "a fantastic job".
US company Eli Lilly has developed a similar therapy.
The novel treatment is a combination or "****tail" of two lab-made antibodies: infection-fighting proteins that were developed to bind to the part of the new coronavirus that it uses to invade human cells.
The antibodies attach themselves to different parts of the virus's spike protein, distorting its structure -- similar in a way to knocking a key out of shape so it no longer fits its lock.
https://www.hindustantimes.com/world-news/germany-to-begin-using-covid-19-medications-that-helped-donald-trump-s-recovery-101611480378687.html
jh, I had to use Hargreaves as Halifax would not allow trade in some other shares I wanted to buy. I have to say the prices I was offered by HL were pretty dreadful. And the telephone trade I was required to make for one trade was appalling both in the time it took, price and an extra 1% commission. So I shall stick with Halifax for share trades as far as possible. I think the strength of HL is fund dealing.
-Foralumab - the only fully human anti-CD3 specific mAb in clinical development.
-Broad potential for a range of inflammatory and autoimmune diseases, nasal and oral administration....a game changer as IV is the goto route.... Which is more toxic for the user and more expensive for the hospital.
-mAb market worth $130 billion by 2025.
-The company is also accelerating the development of TZLS-501, a fully human anti-IL6R mAb, towards the clinic for COVID-19 treatment. The innovative delivery route via handheld nebulizer or inhaler to the lung, directly targets the main site of inflammation.... Which thus far we know has been a success.. And TOPLINE date is due imminelty.....
-All technologies patented!
-Tiziana’s Phase I clinical study of oral Foralumab in Crohn’s Disease showed its proprietary oral formulation of Foralumab to be well tolerated. Phase II trials are planned in H2 20. Its alternative formulation and safety profile could provide a very attractive alternative to IV drugs which include the blockbuster Humira which registered c $4bn in Crohn’s in 2018. Tiziana recently received the first-ever patent on oral delivery of all anti-CD3 monoclonal antibodies for the treatment of human disease supporting the differentiated approach
-Nasal Treatment with Foralumab for secondary progressive MS was well-tolerated in a Phase I trial and induced positive trends in biomarkers of immunomodulation and anti-inflammation in healthy volunteers. Data from these two Phase I trials with alternative oral and nasal routes of administration indicated that the toxicities that are commonly observed with anti-CD3 IV treatment were not observed.
-Fully Funded till 2022
-New chief medical officer from REGENERON! - From 2010 to 2020, Dr Graham was VP of Strategic Program Direction, Immunology and Inflammation at Regeneron Pharmaceuticals, Inc., where he managed and oversaw a large portion of the Regeneron pipeline portfolio including leading the immunology and inflammation antibody products across all stages of development from preclinical to post-launch
-Main market move making TILS more attractive to large institutions.
-Once the results are shown this stock has the potential to go from 160p to £10 very easily.
-Current valuations £700 million... Excluding covid treatment and StemprintER..... Which without any results the current SP should be 400p..... Currently 160p...... Undervalued..... Matter of time until large Personal investors or funds purchase into this biotech stock.
As always do your own research.... This information has been taken from stockopedia and from RNS.. Also tiziana website... Valuations H C Wainwright.
Hargreaves have been posting wrong prices on quite a lot of aim shares for nearly a year. It might not matter to you but take it into account when choosing a new platform. I user them but support is awful
"Successfully spun off StemPrintER business in Q4 2020'"
Perhaps they know when we get our shares listed- apologies in advance!
Agree with all except the last line!
'Investment Highlights
Transformational platform technologies
Proprietary oral, nasal and inhaled formulation technologies to transform immunotherapies with Monoclonal Antibodies currently administered intravenously
Phase 2 oral immunotherapy study for Crohn’s Disease (CD)
Phase 2 clinical study with orally administered Foralumab, a fully human anti-CD3 mAb
Reporting top-line data from COVID-19 trial in Jan. 2021
Innovative technology enables direct delivery of anti-IL6 receptor monoclonal antibodies into the lung using a handheld inhaler or nebulizer
Positive anecdotal feedback from recently completed trial
Could be effective against SARS, MERS, and all variants of coronaviruses
Strong intellectual property protections
174 foreign patents and 19 U.S. patents issued
Proven leadership team with ‘bench to market’ experience
Entrepreneurial success in biotech deals; CEO is co-founder, Synergy Pharma; Executive Chairman founded and chaired two biotechs with $2B+ market caps. Exemplary scientific advisory board with world renowned key opinion leaders
Collaboration with Parexel Biotech to conduct Phase 1b/2 clinical trial in Chron’s patients
Successfully spun off StemPrintER business in Q4 2020'
More like - Spun off Q4 2020, awaiting listing sometime in Q1 2021 at present.
BB
Although Redchip seem a bit of a fly-by-night Company focusing on U.S. Traders they have produced a nice summary page for potential new Investors
https://www.tlsainfo.com/
Hi LBC,
Thanks for your response, I do appreciate it. Yep, agree to disagree.
We appear to be moving on at a pace which is as DCR alludes to not being the norm in this Industry, unexpectedly by the significant movement of priorities towards “ covid “ which is why I believe demerger was moved to a lower priority and the bods be given some slack.
Bestest
Vbw
Phase 3 does represent risk, but more critically represents time...
Approx 50% of drugs that pass phase 2 make it to market, for autoimmune treatments that increases > 60%, so while a risk by the time they get to phase 3 odds are in your favour (most fall by the wayside at ph1/2)...
It's just time consuming...when they get to MS /Crohns, I'd expect that to be c 3 years from now..."if" they get through ph2 this year...
For Covid, i'd assume far quicker...end of this year possibly?
Lol - phase III study represents risk. If we knew the outcome then the study wouldn't be needed. If you don't recognise that then you can delude yourself that you are 100% confident in the share - count chickens, pursue car catalogues, fantasise etc.
Does the SP at current values represent a balance of risk and return. Clearly the market thinks so but they have probably got access to all sorts of experts and advice.
It is a punt and has such it is better as part of a diversified approach. Fingers cosses
Ooh-err, so not so good. Thanks for view, one does need a fair prompt price, Halifax not always great. Hargreaves have been recommended by others. Realise should not complain of tax liability, wish it was HUGE! Take it easy guys (gals?) Gla.
I think it's a hideously bad platform. 5 figure amounts and they hold your sell not for a minute, sometimes ten minutes, same with buys. I sold 16 thousand gbp the other day and they sold them in drabs partial fills. Disgraceful. I have broker called Jarvis. You order a sell, they give you a price, you have 15 seconds to execute and its done. You can even buy a new shares before the settlement hits your balance. Its instant. No BS, no hold up. So i can say how appallingly bad they are as they have stiffed me numerous times. Even tried to buy 16k tils at 170 when they went to 193 when the Nas spiked. Tils went to 193 in about ten minutes, they didn't execute it so i cancelled the transaction and bought more TLSA. In all they cost me 5 to 10 thousand last week. I've had hargreaves before and they are instant too. The Odds are already against us by the spread and they try and steal more off you with the delaying executions.
Thanks all, if not hundal yet. 5 Apr approaches, I've incurred quite enough cgt this fin year.
IG has been a good platform for me over the years.
I use T212. Its easy to use. Had some delays in trying to buy (but who hasn't). I have the share account and my wife has the stocks/shares ISA. App on phone is good, easier than desktop, and the fees suit me.
Again retraces are normal.
Usually to get rid of weak investors then the Whales capitalise on that.... And a new high is formed.
Assume you use this platform, we know they're cheap, would you recommend? I'm currently with Halifax (Lloyds) who aren't great but from what I read not the worst long chalk. (ever hear of short chalk? It's like abetting without aiding.)